Estimated Aggregate Treatment Benefit With Addition of Multiple Novel Medications for Secondary Prevention of Atherosclerotic Cardiovascular Disease
Purpose: Interest in improving residual cardiovascular (CV) risk by targeting multiple causative pathways has been growing. Several medications including icosapent ethyl, rivaroxaban, and ezetimibe have been shown to individually improve outcomes in the secondary prevention of atherosclerotic cardio...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | 図書 |
| 出版事項: |
SAGE Publishing,
2022-03-01T00:00:00Z.
|
| 主題: | |
| オンライン･アクセス: | Connect to this object online. |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
Connect to this object online.3rd Floor Main Library
| 請求記号: |
A1234.567 |
|---|---|
| 所蔵 1 | 利用可 |